
In a groundbreaking study, researchers have conducted the largest network meta-analysis of pharmacotherapy for bipolar depression, shedding light on the most effective treatments. Olanzapine plus fluoxetine, quetiapine, olanzapine, lurasidone, lumateperone, cariprazine, and lamotrigine were found to significantly reduce depressive symptoms with good confidence in the evidence. However, antidepressants carried a higher risk of manic switch compared to antipsychotics. This comprehensive research will shape international treatment guidelines, improving care for adults with acute bipolar depression.
Like
Save
Share